Advertisement
BRKR vs WAT
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Waters Corporation (WAT) Stock Comparison
1. Key Takeaways
- Bruker Corporation (BRKR) and Waters Corporation (WAT) both operate in life science and analytical instrumentation, but their recent trajectories diverge on scale, momentum, and margin quality.
- BRKR delivered steady revenue growth but faced notable margin compression and a year-over-year decline in adjusted earnings per share (EPS), prompting a more cautious analyst tone.
- WAT is executing a transformative acquisition of BD's Biosciences and Diagnostic Solutions businesses, reporting strong organic growth, earnings beats, and raised full-year guidance.
- Tickeron AI Verdict: Based on trend consistency, catalysts, and relative positioning, the AI framework currently favors WAT over BRKR.
- Explore more on each name: BRKR Major News and BRKR Today's Price Move, as well as WAT Major News and WAT Today's Price Move.
- For a broader view of the market, explore Trending AI Robots.
2. Introduction
Investors tracking the life science tools and analytical instrumentation sector frequently weigh Bruker Corporation (BRKR) against Waters Corporation (WAT). Both companies develop high-value scientific instruments used in research, biopharmaceutical, diagnostics, and materials applications, yet they occupy different positions in terms of scale, end-market mix, and recent strategic direction. This comparison is relevant to growth-oriented investors, sector specialists, and traders seeking to understand relative performance and market positioning between two established players navigating shifting research funding, semiconductor demand, and post-acquisition integration dynamics.
3. BRKR Overview and Recent Performance
Bruker Corporation develops and manufactures high-performance scientific instruments and analytical and diagnostic solutions, organized across Bruker Scientific Instruments (BioSpin, CALID, and Nano) and Bruker Energy & Supercon Technologies. The company has broad exposure to life science research, applied markets, semiconductor metrology, and diagnostics.
In recent market activity, BRKR has shown strong one-year price appreciation, with shares trading near the upper half of their 52-week range and a notable run supported by improving relative strength and optimism around semiconductor metrology and AI-driven demand. However, recent quarters have revealed margin pressure: gross margin contracted and adjusted operating income declined year over year, driven by volume and mix shifts plus foreign-exchange and tariff headwinds. Organic revenue declined in the most recent quarter even as acquisitions and currency provided a top-line tailwind. Management reaffirmed full-year guidance, and a recent analyst downgrade to Neutral reflected "incrementally more cautious" sentiment on the near-term outlook, even as other firms maintained or raised price targets. The net picture is one of solid positioning with near-term execution and margin risks in focus.
4. WAT Overview and Recent Performance
Waters Corporation is a global leader in analytical technologies, developing liquid chromatography, mass spectrometry, and thermal analysis instruments, software, and consumables used across pharmaceutical, industrial, and academic applications. A defining recent development is its acquisition of the Biosciences and Diagnostic Solutions businesses from Becton, Dickinson, which closed in early 2026 and significantly expanded the company's scale and diagnostics footprint.
Recent market activity has been constructive for WAT. The company posted double-digit organic constant-currency revenue growth, with orders outpacing sales and particular strength in pharmaceutical demand, including GLP-1 testing and instrument replacement activity. Adjusted EPS grew roughly 20% year over year and beat consensus estimates, while management raised full-year organic growth and adjusted EPS guidance and highlighted early synergy capture from the acquisition. On a GAAP (Generally Accepted Accounting Principles) basis, purchase-accounting charges produced a reported loss, but the underlying operating narrative has been one of broadening momentum across analytical, biosciences, and diagnostics divisions, tempered somewhat by China-related and soft respiratory-testing headwinds.
5. Trending AI Robots
For traders seeking a data-driven edge, Tickeron maintains a curated selection of Trending AI Robots. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and sets of securities. Because not every bot suits every market regime, only those best aligned with current conditions earn a place in the Trending AI Robots section. This helps traders filter for strategies that are performing well in the present environment rather than relying on outdated or generic signals. Explore the Trending AI Robots page to see which automated approaches are currently gaining traction.
6. Head-to-Head Comparison
While both companies serve life science and analytical markets, their business models and risk profiles differ meaningfully. BRKR carries meaningful exposure to academic and government research funding, which has pressured organic growth, alongside a growing semiconductor metrology business tied to AI demand. WAT skews more heavily toward recurring consumables, service, and pharmaceutical end markets, and its recent acquisition added a large diagnostics franchise.
On momentum, WAT has demonstrated more consistent earnings beats, positive organic growth, and upward guidance revisions, whereas BRKR has contended with margin compression and a more mixed analyst response. On scale, WAT is substantially larger by market capitalization. Risk factors also differ: BRKR faces helium-cost, foreign-exchange, and tariff pressures, while WAT carries integration execution risk and China-specific headwinds. Overall, the trade-off is between BRKR's differentiated deep-tech and semiconductor optionality and WAT's broader, more recurring revenue base and current earnings momentum.
7. Tickeron AI Verdict
Weighing observable factors such as trend consistency, earnings catalysts, stability, and relative positioning, Tickeron's AI framework would currently favor WAT over BRKR. The rationale centers on WAT's steadier organic growth, consecutive estimate beats, raised guidance, and a clear synergy-driven catalyst from its recent acquisition, which collectively support a more constructive risk-reward profile in the current environment. BRKR retains long-term appeal through its semiconductor metrology and spatial biology franchises, but near-term margin pressure and a more cautious analyst stance temper its relative positioning. This assessment reflects a probabilistic reading of current data rather than a definitive prediction.
8. Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a Hold and WAT is a Hold.
Momentum Indicator for BRKR turns positive, indicating new upward trend
BRKR saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 76 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BRKR just turned positive on October 27, 2026. Looking at past instances where BRKR's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +6.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKR advanced for three days, in 198 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 64 cases where BRKR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
BRKR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BRKR crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRKR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
BRKR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.615) is normal, around the industry mean (4.204). P/E Ratio (-80.714) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (1.070) is also within normal values, averaging (11.253). Dividend Yield (0.004) settles around the average of (0.010) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. BRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
WAT in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 27, 2026
WAT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 25 of the 38 cases the stock fell afterwards. This puts the odds of success at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for WAT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 21 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 70 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on WAT as a result. In 60 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on October 21, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +2.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 179 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.907) is normal, around the industry mean (65.986). WAT has a moderately high P/E Ratio (112.947) as compared to the industry average of (3.066). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
BRKR | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 57 | |
SMR RATING 1..100 | 92 | 89 | |
PRICE GROWTH RATING 1..100 | 43 | 10 | |
P/E GROWTH RATING 1..100 | 45 | 2 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (9) in the Medical Specialties industry is significantly better than the same rating for WAT (90). This means that BRKR’s stock grew significantly faster than WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (57) in the Medical Specialties industry is somewhat better than the same rating for BRKR (100). This means that WAT’s stock grew somewhat faster than BRKR’s over the last 12 months.
WAT's SMR Rating (89) in the Medical Specialties industry is in the same range as BRKR (92). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
WAT's Price Growth Rating (10) in the Medical Specialties industry is somewhat better than the same rating for BRKR (43). This means that WAT’s stock grew somewhat faster than BRKR’s over the last 12 months.
WAT's P/E Growth Rating (2) in the Medical Specialties industry is somewhat better than the same rating for BRKR (45). This means that WAT’s stock grew somewhat faster than BRKR’s over the last 12 months.
| BRKR | WAT | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 64% |
| Advances ODDS (%) | 7 days ago 69% | 6 days ago 64% |
| Declines ODDS (%) | 2 days ago 74% | 2 days ago 62% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 66% |
| Aroon ODDS (%) | N/A | 2 days ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while WAT’s FA Score has 2 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 3 TA indicator(s) are bullish while WAT’s TA Score has 4 bullish TA indicator(s).
- BRKR’s TA Score: 3 bullish, 5 bearish.
- WAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а -4.36% price change this week, while WAT (@Medical Specialties) price change was -1.41% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.01%. For the same industry, the average monthly price growth was -6.09%, and the average quarterly price growth was -8.21%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.34%. For the same industry, the average monthly price growth was -5.26%, and the average quarterly price growth was +42.07%.
Reported Earning Dates
BRKR is expected to report earnings on Nov 04, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical/Nursing Services (+0.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-2.34% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | +1.45% | ||
| A - BRKR | 78% Closely correlated | +2.02% | ||
| MTD - BRKR | 75% Closely correlated | +1.18% | ||
| WAT - BRKR | 68% Closely correlated | +2.31% | ||
| RVTY - BRKR | 68% Closely correlated | +7.84% | ||
| TMO - BRKR | 66% Loosely correlated | +2.30% | ||
More | ||||
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been loosely correlated with A. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | +2.31% | ||
| A - WAT | 65% Loosely correlated | +2.02% | ||
| RVTY - WAT | 60% Loosely correlated | +7.84% | ||
| BRKR - WAT | 58% Loosely correlated | +1.45% | ||
| TMO - WAT | 57% Loosely correlated | +2.30% | ||
| CRL - WAT | 57% Loosely correlated | +3.94% | ||
More | ||||